Phospho-SF1 (Ser82) antibody is a rabbit polyclonal antibody targeting the phosphorylated form of SF1 at Ser82. SF1 (UniProt ID: Q15637) facilitates spliceosome assembly by binding to the branch point sequence (BPS) of pre-mRNA and regulates transcription. Phosphorylation at Ser82 modulates SF1’s interaction with U2AF2, affecting spliceosome dynamics .
The antibody was generated using a synthesized non-phosphopeptide derived from human SF1 around Ser82. Key features include:
Epitope: Phosphorylated Ser82 within the sequence S-P-SP-P-E .
Cross-Reactivity: Validated in human tissues (e.g., lung cancer samples ) and mouse/rat models. Predictions extend to pig, zebrafish, and bovine .
Validation: Specificity confirmed via blocking peptides (e.g., AF7395-BP), which eliminate signal in WB when pre-incubated with the target peptide .
Phosphorylation at Ser82 disrupts SF1’s interaction with U2AF2, impairing spliceosome assembly. This modification is critical for:
Transcriptional Repression: SF1 binds EWSR1, FUS, and TAF15 to regulate RNA processing .
Cellular Localization: Phosphorylated SF1 is predominantly nuclear .
Cancer: Detected in lung cancer tissues via IHC, suggesting a role in oncogenic splicing alterations .
Neurological Disorders: Interactions with RNA-binding proteins (e.g., RBM17) implicate SF1 in neurodegenerative diseases .
Blocking Peptides: Available for competitive assays (e.g., AF7395-BP) .
Phospho-Specificity: Does not recognize non-phosphorylated SF1 or SF1 phosphorylated at other residues .